Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends RA drug

The UK's National Institute for Health and Clinical Excellence has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis drug Simponi in specific, limited circumstances

The UK's National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis (RA) drug Simponi (golimumab) for use on the NHS in specific, limited circumstances.

The drug is recommended for adults with severe active RA used in combination with methotrexate in cases where 'conventional' disease-modifying antirheumatic drugs (DMARDs) have been ineffective.

It is also recommended for similar patients who have tried other types of DMARDs, including a tumour necrosis factor (TNF) inhibitor, but these treatments have also been ineffective and the patient is unable to take rituximab therapy for medical reasons or because of a previous bad reaction.

Dr Carole Longson, Health Technology Evaluation Centre director at NICE said: "This final guidance sets out the circumstances where golimumab can now be offered by the NHS as a treatment option for people with rheumatoid arthritis for whom previous treatments have not worked.

"Rheumatoid arthritis treatments help to relieve pain, improve mobility and reduce the long-term damage often experienced by people with this condition."

22nd June 2011

From: Healthcare

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics